| 摘要 |
The present invention relates to the use of cannabinoid receptor agonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of cannabinoid receptor agonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation such as regurgitation in infants, lung disease, chronic laryngitis and asthma.
|
